Cécile Mauborgne

Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial

Christophe Le Tourneau, Jean-Pierre Delord, Anthony Gonçalvès et al. · The Lancet Oncology · 2015 · 1.1K citations

Advanced Cancer, Drug Targeting, Oncology +12

Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial

Lisa Belin, Maud Kamal, Cécile Mauborgne et al. · Annals of Oncology · 2016 · 83 citations · Full text

Medicine, Versus Conventional Therapy, Clinical Trials +11

Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial

Christophe Le Tourneau, Xavier Paolettí, Nicolas Servant et al. · British Journal of Cancer · 2014 · 70 citations · Full text